Associated Papers
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
Yaeger R et al.
Cancer Discovery, 2024
38691346 (PubMed )
Supplement: cd-24-0024_table_s5_suppst5.pdf
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_4.xlsx › EGFR_mutations
Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population With Non-small Cell Lung Cancer.
Kahraman Çetin N et al.
Balkan Medical Journal, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
Dagogo-Jack I et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2021
Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients.
Li H et al.
Frontiers in Oncology, 2020
33747896 (PubMed )
Supplement: Table_1.xlsx › Table_S2
Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.
Muller E et al.
Cancer Medicine, 2015
Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family.
Simard J et al.
Endocrine Reviews, 2005
Select a paper to view details